The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms

Infection and Immunity

Volumn 78, Issue 2, 2010, Pages 704-715

  Hyams, Catherine ^a   Camberlein, Emilie ^a   Cohen, Jonathan M ^a   Bax, Katie ^b   Brown, Jeremy S ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; BACTERIUM ANTIBODY; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3B; COMPLEMENT FACTOR I; COMPLEMENT RECEPTOR; FC RECEPTOR; IMMUNOGLOBULIN G; OPSONIN; STREPTOCOCCUS ANTIGEN;

ARTICLE; BACTERIAL MEMBRANE; BACTERIUM MUTANT; BINDING AFFINITY; CELLULAR IMMUNITY; COMPLEMENT SYSTEM; CONTROLLED STUDY; INCUBATION TIME; INHIBITION KINETICS; MOLECULAR RECOGNITION; NEUTROPHIL; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE;

BACTERIAL CAPSULES; CELL SEPARATION; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; NEUTROPHILS; PHAGOCYTOSIS; STREPTOCOCCUS PNEUMONIAE; VIRULENCE;

EID: 76749095490     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00881-09     Document Type: Article

References (53)

1. Abeyta, M., G. G. Hardy, and J. Yother. 2003. Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae. Infect. Immun. 71:218-225.
2. Arredouani, M., Z. Yang, Y. Ning, G. Qin, R. Soininen, K. Tryggvason, and L. Kobzik. 2004. The scavenger receptor MARCO is required for lung defense against pneumococcal pneumonia and inhaled particles. J. Exp. Med. 200:267-272.
3. Arredouani, M. S., Z. Yang, A. Imrich, Y. Ning, G. Qin, and L. Kobzik. 2006. The macrophage scavenger receptor SR-AI/II and lung defense against pneumococci and particles. Am. J. Respir. Cell Mol. Biol. 35:474-478.
4. Baxendale, H. E., M. Johnson, R. C. Stephens, J. Yuste, N. Klein, J. S. Brown, and D. Goldblatt. 2008. Natural human antibodies to pneumococcus have distinctive molecular characteristics and protect against pneumococcal disease. Clin. Exp. Immunol. 151:51-60.
5. Bentley, S. D., D. M. Aanensen, A. Mavroidi, D. Saunders, E. Rabbinowitsch, M. Collins, K. Donohoe, D. Harris, L. Murphy, M. A. Quail, G. Samuel, I. C. Skovsted, M. S. Kaltoft, B. Barrell, P. R. Reeves, J. Parkhill, and B. G. Spratt. 2006. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. PLoS Genet. 2:e31.
6. Briles, D. E., M. J. Crain, B. M. Gray, C. Forman, and J. Yother. 1992. Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect. Immun. 60:111-116.
7. Briles, D. E., M. Nahm, K. Schroer, J. Davie, P. Baker, J. Kearney, and R. Barletta. 1981. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 Streptococcus pneumoniae. J. Exp. Med. 153:694-705.
8. Brown, J. S., T. Hussell, S. M. Gilliland, D. W. Holden, J. C. Paton, M. R. Ehrenstein, M. J. Walport, and M. Botto. 2002. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc. Natl. Acad. Sci. U. S. A. 99:16969-16974.
9. Brueggemann, A. B., T. E. Peto, D. W. Crook, J. C. Butler, K. G. Kristinsson, and B. G. Spratt. 2004. Temporal and geographic stability of the serogroupspecific invasive disease potential of Streptococcus pneumoniae in children. J. Infect. Dis. 190:1203-1211.
10. Bryce, J., C. Boschi-Pinto, K. Shibuya, and R. E. Black. 2005. WHO estimates of the causes of death in children. Lancet 365:1147-1152.
11. Burton, R. L., and M. H. Nahm. 2006. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin. Vaccine Immunol. 13:1004-1009.
12. Daniels, C. C., T. C. Briles, S. Mirza, A. P. Hakansson, and D. E. Briles. 2006. Capsule does not block antibody binding to PspA, a surface virulence protein of Streptococcus pneumoniae. Microb. Pathog. 40:228-233.
13. Dempsey, P. W., M. E. Allison, S. Akkaraju, C. C. Goodnow, and D. T. Fearon. 1996. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271:348-350.
14. Edstrom, R. D. 1969. A colorimetric method for the determination of mucopolysaccharides and other acidic polymers. Anal. Biochem. 29:421-432.
15. Gross, G. N., S. R. Rehm, and A. K. Pierce. 1978. The effect of complement depletion on lung clearance of bacteria. J. Clin. Investig. 62:373-378.
16. Hammerschmidt, S., S. Wolff, A. Hocke, S. Rosseau, E. Muller, and M. Rohde. 2005. Illustration of pneumococcal polysaccharide capsule during adherence and invasion of epithelial cells. Infect. Immun. 73:4653-4667.
17. Hostetter, M. K. 1986. Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b: implications for phagocytosis and antibody production. J. Infect. Dis. 153:682-693.
18. Jacobs, M. R., C. E. Good, S. Bajaksouzian, and A. R. Windau. 2008. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the proteinconjugated pneumococcal vaccine. Clin. Infect. Dis. 47:1388-1395.
19. Jonsson, G., L. Truedsson, G. Sturfelt, V. A. Oxelius, J. H. Braconier, and A. G. Sjoholm. 2005. Hereditary C2 deficiency in Sweden: frequent occurrence of invasive infection, atherosclerosis, and rheumatic disease. Medicine (Baltimore) 84:23-34.
20. Kang, Y. S., Y. Do, H. K. Lee, S. H. Park, C. Cheong, R. M. Lynch, J. M. Loeffler, R. M. Steinman, and C. G. Park. 2006. A dominant complement fixation pathway for pneumococcal polysaccharides initiated by SIGN-R1 interacting with C1q. Cell 125:47-58.
21. Kelly, T., J. P. Dillard, and J. Yother. 1994. Effect of genetic switching of capsular type on virulence of Streptococcus pneumoniae. Infect. Immun. 62:1813-1819.
22. Khandavilli, S., K. A. Homer, J. Yuste, S. Basavanna, T. Mitchell, and J. S. Brown. 2008. Maturation of Streptococcus pneumoniae lipoproteins by a type II signal peptidase is required for ABC transporter function and full virulence. Mol. Microbiol. 67:541-557.
23. Kugelberg, E., B. Gollan, and C. M. Tang. 2008. Mechanisms in Neisseria meningitidis for resistance against complement-mediated killing. Vaccine 26(Suppl. 8):I34-I39.
24. Lu, L., Y. Ma, and J. R. Zhang. 2006. Streptococcus pneumoniae recruits complement factor H through the amino terminus of CbpA. J. Biol. Chem. 281:15464-15474.
25. Marques, M. B., D. L. Kasper, M. K. Pangburn, and M. R. Wessels. 1992. Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect. Immun. 60:3986-3993.
26. Maruvada, R., N. V. Prasadarao, and C. E. Rubens. 2009. Acquisition of factor H by a novel surface protein on group B Streptococcus promotes complement degradation. FASEB J. 23:3967-3977.
27. Mavroidi, A., D. Godoy, D. M. Aanensen, D. A. Robinson, S. K. Hollingshead, and B. G. Spratt. 2004. Evolutionary genetics of the capsular locus of serogroup 6 pneumococci. J. Bacteriol. 186:8181-8192.
28. Morona, J. K., D. C. Miller, R. Morona, and J. C. Paton. 2004. The effect that mutations in the conserved capsular polysaccharide biosynthesis genes cpsA, cpsB, and cpsD have on virulence of Streptococcus pneumoniae. J. Infect. Dis. 189:1905-1913.
29. Morona, J. K., R. Morona, and J. C. Paton. 2006. Attachment of capsular polysaccharide to the cell wall of Streptococcus pneumoniae type 2 is required for invasive disease. Proc. Natl. Acad. Sci. U. S. A. 103:8505-8510.
30. Nelson, A. L., A. M. Roche, J. M. Gould, K. Chim, A. J. Ratner, and J. N. Weiser. 2007. Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance. Infect. Immun. 75:83-90.
31. Neth, O., D. L. Jack, A. W. Dodds, H. Holzel, N. J. Klein, and M. W. Turner. 2000. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect. Immun. 68:688-693.
32. Quin, L. R., Q. C. Moore III, and L. S. McDaniel. 2007. Pneumolysin, PspA, and PspC contribute to pneumococcal evasion of early innate immune responses during bacteremia in mice. Infect. Immun. 75:2067-2070.
33. Roche, A. M., S. J. King, and J. N. Weiser. 2007. Live attenuated Streptococcus pneumoniae strains induce serotype-independent mucosal and systemic protection in mice. Infect. Immun. 75:2469-2475.
34. Segal, A. W., and O. T. Jones. 1980. Absence of cytochrome b reduction in stimulated neutrophils from both female and male patients with chronic granulomatous disease. FEBS Lett. 110:111-114.
35. Serrano, I., J. Melo-Cristino, and M. Ramirez. 2006. Heterogeneity of pneumococcal phase variants in invasive human infections. BMC Microbiol. 6:67.
36. Szalai, A. J., D. E. Briles, and J. E. Volanakis. 1996. Role of complement in C-reactive-protein-mediated protection of mice from Streptococcus pneumoniae. Infect. Immun. 64:4850-4853.
37. Tomás, J. M., S. Camprubi, S. Merino, M. R. Davey, and P. Williams. 1991. Surface exposure of O1 serotype lipopolysaccharide in Klebsiella pneumoniae strains expressing different K antigens. Infect. Immun. 59:2006-2011.
38. Trzcinski, K., C. M. Thompson, and M. Lipsitch. 2003. Construction of otherwise isogenic serotype 6B, 7F, 14, and 19F capsular variants of Streptococcus pneumoniae strain TIGR4. Appl. Environ. Microbiol. 69:7364-7370.
39. Tu, A. H., R. L. Fulgham, M. A. McCrory, D. E. Briles, and A. J. Szalai. 1999. Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect. Immun. 67:4720-4724.
40. Volanakis, J. E. 2001. Human C-reactive protein: expression, structure, and function. Mol. Immunol. 38:189-197.
41. von Pawel-Rammingen, U., B. P. Johansson, and L. Bjorck. 2002. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J. 21:1607-1615.
42. Walport, M. J. 2001. Complement-first of two parts. N. Engl. J. Med. 344:1058-1066.
43. Watson, D., and D. Musher. 1990. Interruption of capsule production in Streptococcus pneumoniae serotype 3 by insertion of transposon Tn916. Infect. Immun. 58:3135-3138.
44. Weinberger, D. M., K. Trzcinski, Y. J. Lu, D. Bogaert, A. Brandes, J. Galagan, P. W. Anderson, R. Malley, and M. Lipsitch. 2009. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog. 5:e1000476.
45. Wenig, K., L. Chatwell, U. von Pawel-Rammingen, L. Bjorck, R. Huber, and P. Sondermann. 2004. Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG. Proc. Natl. Acad. Sci. U. S. A. 101:17371-17376.
46. Wessels, M. R., C. E. Rubens, V. J. Benedi, and D. L. Kasper. 1989. Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule. Proc. Natl. Acad. Sci. U. S. A. 86:8983-8987.
47. Winkelstein, J. A. 1981. The role of complement in the host's defense against Streptococcus pneumoniae. Rev. Infect. Dis. 3:289-298.
48. Winkelstein, J. A., J. A. Bocchini, Jr., and G. Schiffman. 1976. The role of the capsular polysaccharide in the activation of the alternative pathway by the pneumococcus. J. Immunol. 116:367-370.
49. Wood, W. B., Jr., and M. R. Smith. 1949. The inhibition of surface phagocytosis by the capsular slime layer of pneumococcus type III. J. Exp. Med. 90:85-96.
50. Young, B. J., and T. R. Kozel. 1993. Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans. Infect. Immun. 61:2966-2972.
51. Yuste, J., M. Botto, S. E. Bottoms, and J. S. Brown. 2007. Serum amyloid P aids complement-mediated immunity to Streptococcus pneumoniae. PLoS Pathog. 3:1208-1219.
52. Yuste, J., M. Botto, J. C. Paton, D. W. Holden, and J. S. Brown. 2005. Additive inhibition of complement deposition by pneumolysin and PspA facilitates Streptococcus pneumoniae septicemia. J. Immunol. 175:1813-1819.
53. Yuste, J., A. Sen, L. Truedsson, G. Jonsson, L. S. Tay, C. Hyams, H. E. Baxendale, F. Goldblatt, M. Botto, and J. S. Brown. 2008. Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in serum from subjects with defects in the classical complement pathway. Infect. Immun. 76:3761-3770.